Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Label-Free Analyses of Minimal Residual Disease in ALL Using Deep Learning and Imaging Flow Cytometry

Minh Doan, Marian Case, Dino Mašić, PhD, Holger Hennig, Claire McQuin, Allen Goodman, Juan Caicedo, Olaf Wolkenhauer, Huw Summers, Anne E Carpenter, Andy Filby, Paul Rees, Julie Irving, PhD

Blood (2017) 130 (Supplement 1): 1437.

https://doi.org/10.1182/blood.V130.Suppl_1.1437.1437

Published: 2017

Journal Articles

Exploring Pre-B Cell Receptor Signalling As a Therapeutic Target in Acute Lymphoblastic Leukaemia

Ali Alhammer, M.Sc, Marian Case, MSc, Helen J Blair, PhD, Josef Vormoor, MD FRCPCH, Julie Irving, PhD

Blood (2016) 128 (22): 4066.

https://doi.org/10.1182/blood.V128.22.4066.4066

Published: 2016

Journal Articles

Validation of MRD Quantification By Flow Cytometry for Pediatric BCP ALL Relapsed Patients Treated on the Intreall Protocol

Blood (2015) 126 (23): 1414.

https://doi.org/10.1182/blood.V126.23.1414.1414

Published: 2015

Journal Articles

Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition

Julie Irving, Elizabeth Matheson, Lynne Minto, Helen Blair, Marian Case, Christina Halsey, Isabella Swidenbank, Frida Ponthan, Renate Kirschner-Schwabe, Stefanie Groeneveld-Krentz, Jana Hof, James Allan, Christine Harrison, Josef Vormoor, Arend von Stackelberg, Cornelia Eckert

Blood (2014) 124 (23): 3420–3430.

https://doi.org/10.1182/blood-2014-04-531871

Published: 2014

Includes: Supplemental data

Journal Articles

RAS Pathway Mutations Are Highly Prevalent In Relapsed Childhood Acute Lymphoblastic Leukaemia, Are Frequently Relapse-Drivers and Confer Sensitivity To MEK Inhibition

Julie Irving, PhD, Elizabeth C. Matheson, MPhil, Lynne Minto, Helen Blair, PhD, Marian Case, MSc, Christina Halsey, MD, PhD, Isabella Swidenbank, MRes, Frida Ponthan, PhD, Renate Kirschner-Schwabe, PhD, Stefanie Groeneveld-Krentz, MSc, Jana Hof, MSc, James Allan, PhD, Christine J. Harrison, PhD, Josef Vormoor, MD, Arend Stackelberg, MD, Cornelia Eckert, PhD

Blood (2013) 122 (21): 823.

https://doi.org/10.1182/blood.V122.21.823.823

Published: 2013

Journal Articles

In Childhood ALL, Both Blasts with a CD20 −/Low and a CD20 High Immunophenotype Have the Ability to Transfer the Leukemia Onto Immune-Deficient NOD/Scid Y −/− Mice.

Kerrie Wilson, BSc(Hons), Klaus Rehe, MD, Simon Bomken, MD, Marian Case, MSc, Leonard Shultz, PhD, Julie Irving, PhD, Josef Vormoor, MD, FRCPCH

Blood (2008) 112 (11): 1348.

https://doi.org/10.1182/blood.V112.11.1348.1348

Published: 2008

Journal Articles

The CD34 + CD38 Low CD19 + Candidate Leukemic Stem Cell Phenotype Revisited: Useful for Flow MRD Monitoring?

Kerrie Wilson, BSc(Hons), Marian Case, MSc, Lynne Minto, Simon Bailey, MD, PhD, FRCPCH, Josef Vormoor, MD, FRCPCH, Julie Irving, PhD

Blood (2008) 112 (11): 2505.

https://doi.org/10.1182/blood.V112.11.2505.2505

Published: 2008

Journal Articles

Mutation in Genes Impacting on the RAS-RAF-MEK-ERK Pathway Are Found at High Incidence in Childhood Acute Lymphoblastic Leukemia at Both Diagnosis and at Relapse.

Julie Irving, Lynne Minto, Elizabeth Matheson, Marian Case, Simon Bailey, Nick Bown, Rosline Hassan, Christine Harrison, Andrew Hall

Blood (2006) 108 (11): 4328.

https://doi.org/10.1182/blood.V108.11.4328.4328

Published: 2006

Journal Articles

Comprehensive Analysis of p16 INK4a in Childhood Acute Lymphoblastic Leukemia Reveals Homozygous Deletion, Haploinsufficiency and Acquired Isodisomy at the 9p Locus with Intact p16 INK4a .

Sarina Sulong, Julie Irving, Marian Case, Lynne Minto, Nick Bown, Simon Bailey, Christine Harrison, Andrew Hall

Blood (2006) 108 (11): 4332.

https://doi.org/10.1182/blood.V108.11.4332.4332

Published: 2006

NARROW

Label-Free Analyses of Minimal Residual Disease in ALL Using Deep Learning and Imaging Flow Cytometry

Exploring Pre-B Cell Receptor Signalling As a Therapeutic Target in Acute Lymphoblastic Leukaemia

Validation of MRD Quantification By Flow Cytometry for Pediatric BCP ALL Relapsed Patients Treated on the Intreall Protocol

Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition

RAS Pathway Mutations Are Highly Prevalent In Relapsed Childhood Acute Lymphoblastic Leukaemia, Are Frequently Relapse-Drivers and Confer Sensitivity To MEK Inhibition

In Childhood ALL, Both Blasts with a CD20 −/Low and a CD20 High Immunophenotype Have the Ability to Transfer the Leukemia Onto Immune-Deficient NOD/Scid Y −/− Mice.

The CD34 + CD38 Low CD19 + Candidate Leukemic Stem Cell Phenotype Revisited: Useful for Flow MRD Monitoring?

Mutation in Genes Impacting on the RAS-RAF-MEK-ERK Pathway Are Found at High Incidence in Childhood Acute Lymphoblastic Leukemia at Both Diagnosis and at Relapse.

Comprehensive Analysis of p16 INK4a in Childhood Acute Lymphoblastic Leukemia Reveals Homozygous Deletion, Haploinsufficiency and Acquired Isodisomy at the 9p Locus with Intact p16 INK4a .

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only